Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | April 03, 2026 | April 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Stoke Therapeutics, Inc.
Report date April 03, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79 · Expires 2036-04-02 | Direct | 30,782 |
Reported balance
After 2026-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-03 · Grant · Acquired 30,782 · Balance 30,782 F1: The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267496 · ownership.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 23:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 30,782 | $0.00 Strike: $32.79 | $0.00 |
DisclosureSEC source: 0001849236-26-000004 · form4-04072026_110410.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,782 Underlying: Common Stock · 30,782 shares Expires 2036-04-02 F1 · derivative.exercise_date: The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-086236 · ownership.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchaseCommon Stock | 1,860 | $5.34 | $9,924.40 |
DisclosureSEC source: 0000950170-25-038706 · ownership.xml · nonDerivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,960 Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-072996 · ownership.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 18:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchaseCommon Stock | 1,100 | $7.67 | $8,441.62 |
DisclosureSEC source: 0000950170-24-071765 · ownership.xml · nonDerivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-015007 · doc4.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F1 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000899243-22-038686 · doc4.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2032-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035457 · doc4.xml · derivative · entry 2 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-07 F2 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in equal quarterly installments over the 12 month period following the grant date, subject to continued service as a director or consultant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035457 · doc4.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:37 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-21-017929 · doc4.xml · derivative · entry 1 Kahn Clare · CIK 0001849236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in three equal annual installments on the anniversary of the grant date, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.